Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05194072 · ClinicalTrials.gov registry record · Phase 1
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
A Phase 1 study, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
NCT05194072: Clinical Trial Phase 1 study, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
NCT05194072 is a Phase 1 study that was terminated before completion, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 250 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (317% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05194072, a Phase 1 study, was terminated before completion, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
Study Summary
The purpose of the study is to test the safety of the medicine called Felmetatug Vedotin alone and with pembrolizumab in participants with solid tumors. It will also look at the side effects of this medicine. A side effect is anything a medicine does to the body besides treating the disease. This study is seeking for participants who either have cancer: * that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable), * has spread through the body (metastatic), or have some cancer left over after surgery. This study will have five parts. * Parts A and B of the study will find out how much Felmetatug Vedotin should be given to participants. * Part C will use the amount found in Parts A and B to find out how safe Felmetatug Vedotin is and if it works to treat solid tumor cancers. * Part D will find out if and how much Felmetatug Vedotin can be given with pembrolizumab. * Part E will use the amount found in Part D to find out how safe Felmetatug Vedotin with pembrolizumab is and if it works to treat triple negative breast cancer.
Primary Outcome
Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Interventions
- DRUG Pembrolizumab
- DRUG Felmetatug Vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2022-01-12 |
| Est. Completion | 2025-05-14 |
| Phase | Phase 1 |
Why NCT05194072 stopped before completion
NCT05194072 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (317% higher).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05194072 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05194072 about?
NCT05194072 is a clinical study titled "A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors". The purpose of the study is to test the safety of the medicine called Felmetatug Vedotin alone and with pembrolizumab in participants with solid tumors. It will also look at the side effects of this medicine. A side effect is anything a medicine does to the body besides treating the disease. This s...
What is the current status of trial NCT05194072?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2022-01-12. Estimated completion is 2025-05-14.
What interventions are being tested in trial NCT05194072?
The interventions under investigation include: Pembrolizumab (DRUG), Felmetatug Vedotin (DRUG).
Who is sponsoring clinical trial NCT05194072?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05194072's enrollment target sits among peer trials
250 173rd of 2000 higher than 1,816 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI